Researchers seek $5 billion annual investment to fight superbugs

25 August 2016

At least $5 billion will be needed each year to effectively tackle drug-resistant infections, researchers believe.

These experts want a World Bank Trust Fund to coordinate the response to this growing public health crisis, with growing resistance leading to the emergence of superbugs that can cause life-threatening infections such as methicillin resistant staphylococcus aureus (MRSA) and drug-resistant tuberculosis.

Outlining their proposals in the journal Science, the researchers from the US Center for Disease Dynamics, Economics and Policy, the University of Edinburgh, New York University and Fudan University in China have said that confronting the problem will require a coordinated global response.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK